Yuvan Research Inc., a longevity biotech startup, has developed a new formulation of the naturally occurring peptide GHK-Cu to increase skin collagen density.
GHK-Cu activates or deactivates 31.2% of human genes, triggering epigenetic alterations in the cells, which can help to reverse age-related skin thinning.
In a clinical trial conducted by Dr. Wayne Carey at McGill University, participants used the GHK-Cu formulation for three months.
Using ultra-high resolution ultrasound imaging, researchers observed an average increase of 28% in subdermal echogenic density, which correlates with collagen and elastin elements. The top quartile of participants saw an average 51% improvement in collagen.
GHK-Cu's epigenetic modulation effects have only been understood recently, after advancements in biomedical technology and gene sequencing.
The novel formulation developed by Yuvan provides greater stability to GHK-Cu and facilitates its transdermal delivery.
GHK-Cu was found to possess powerful cell-protective actions, such as anti-cancer activities and anti-inflammatory actions, in addition to improved DNA repair and proteasome function.
Yuvan Research's GHK-Cu-based gel, called "Neel", is now available to the public on Amazon.com and neelgel.com.
